Zetia

Zetia. It is a medication used to treat high levels of cholesterol in the blood, specifically as an adjunct to diet and often in combination with other agents like statins. Marketed by Merck & Co., its generic name is ezetimibe, and it functions by selectively inhibiting the absorption of cholesterol from the small intestine. This distinct mechanism offers a therapeutic option for patients who cannot tolerate sufficient doses of statins or require additional cholesterol-lowering.

Medical uses

Zetia is indicated for the reduction of elevated low-density lipoprotein (LDL) cholesterol, either as monotherapy or in combination with a hydroxymethylglutaryl-coenzyme A reductase inhibitor. It is used in patients with primary hyperlipidemia, including those with the genetic disorder homozygous familial hypercholesterolemia, often alongside other treatments. Clinical trials, such as the IMPROVE-IT trial, demonstrated its benefit in reducing cardiovascular events when added to simvastatin in patients post-acute coronary syndrome. It may also be combined with fenofibrate for treating mixed dyslipidemia, under careful monitoring by a physician.

Mechanism of action

Ezetimibe works locally at the brush border of the small intestine by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is critical for the intestinal uptake of dietary and biliary cholesterol. This action prevents the cholesterol from being incorporated into chylomicrons for transport to the liver, leading to a decrease in the delivery of intestinal cholesterol to the liver. Consequently, the liver upregulates LDL receptors, increasing clearance of LDL cholesterol from the bloodstream, a pathway complementary to that of drugs like atorvastatin or rosuvastatin.

Adverse effects

Common adverse effects include fatigue, diarrhea, and upper respiratory tract infections, while musculoskeletal pain has also been reported. Rare but serious potential effects involve hepatotoxicity, as evidenced by elevations in serum transaminase levels, and myopathy, including rhabdomyolysis, particularly when co-administered with a statin. Hypersensitivity reactions, such as angioedema and rash, have been documented. Postmarketing surveillance has noted reports of thrombocytopenia, and physicians are advised to monitor for signs of liver injury through tests like the alanine transaminase assay.

Pharmacokinetics

Following oral administration, ezetimibe is absorbed and extensively metabolized in the small intestine and liver to its active phenolic glucuronide metabolite. The parent drug and metabolite are highly bound to human serum albumin, exceeding 90% protein binding. The terminal half-life is approximately 22 hours, supporting once-daily dosing. The primary route of excretion is via the feces, with a minor portion eliminated in the urine, and no significant pharmacokinetic differences are noted based on age, gender, or renal impairment, though caution is advised in patients with moderate to severe hepatic insufficiency.

History and society

Ezetimibe was discovered and developed by the pharmaceutical company Schering-Plough, with key research conducted at the Texas Heart Institute and other centers. It received approval from the U.S. Food and Drug Administration in 2002, following review of data from clinical trials like the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression study. Its development and marketing were later impacted by the merger of Merck & Co. and Schering-Plough in 2009. The drug's role was further defined by large outcomes studies, including the SHARP trial, which investigated its use in patients with chronic kidney disease, contributing to its inclusion in treatment guidelines from the American Heart Association.